scholarly journals Jejunal Fistula Complicating Ovarian Serous Carcinoma: Case Report of a Rare Phenomenon and Review of the Literature

2019 ◽  
pp. 1
Author(s):  
Isin Ureyen ◽  
Tayfun Toptas ◽  
Sezin Ates Tatar ◽  
Gulsum Ekin ◽  
Faruk Gulec ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Abdominal Pain ◽  
Digestive System ◽  
The Other ◽  
Serous Carcinoma ◽  
Fistula Formation ◽  
Ovarian Cancer Cells ◽  
Review Of The Literature ◽  
Ovarian Serous Carcinoma ◽  
Small Intestines

<p>Invasion of the wall of the digestive system by ovarian cancer cells isn’t so rare. On the other hand, fistula formation between the tumor and digestive system is an uncommon status. We described a patient with ovarian serous carcinoma that was fistulized into jejenum and formed a region composed of stool and tumor surrounded and limited by small intestines recognized during surgery. This diagnosis should be kept in mind while preparing a patient for ovarian cancer surgery if the patient has acute abdomen or abdominal pain incompatible with the extent of the tumor.</p>

scholarly journals Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients

2013 ◽  
Vol 20 (2) ◽  
pp. 213-227 ◽  
Author(s):  
Ying-Cheng Chiang ◽  
Ming-Cheng Chang ◽  
Pao-Jen Chen ◽  
Meei-Maan Wu ◽  
Chang-Yao Hsieh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Multivariate Analysis ◽  
Poor Prognosis ◽  
Methylation Status ◽  
Progression Free Survival ◽  
Serous Carcinoma ◽  
Ovarian Cancer Cells ◽  
Advanced Stage ◽  
Ovarian Serous Carcinoma

Epithelial ovarian carcinoma is usually present at the advanced stage, during which the patients generally have poor prognosis. Our study aimed to evaluate the correlation of gene methylation and the clinical outcome of patients with advanced-stage, high-grade ovarian serous carcinoma. The methylation status of eight candidate genes was first evaluated by methylation-specific PCR and capillary electrophoresis to select three potential genes including DAPK, CDH1, and BLU (ZMYND10) from the exercise group of 40 patients. The methylation status of these three genes was further investigated in the validation group consisting of 136 patients. Patients with methylated BLU had significantly shorter progression-free survival (PFS; hazard ratio (HR) 1.48, 95% CI 1.01–2.56, P=0.013) and overall survival (OS; HR 1.83, 95% CI 1.07–3.11, P=0.027) in the multivariate analysis. Methylation of BLU was also an independent risk factor for 58 patients undergoing optimal debulking surgery for PFS (HR 2.37, 95% CI 1.03–5.42, P=0.043) and OS (HR 3.96, 95% CI 1.45–10.81, P=0.007) in the multivariate analysis. A possible mechanism of BLU in chemoresistance was investigated in ovarian cancer cell lines by in vitro apoptotic assays. In vitro studies have shown that BLU could upregulate the expression of BAX and enhance the effect of paclitaxel-induced apoptosis in ovarian cancer cells. Our study suggested that methylation of BLU could be a potential prognostic biomarker for advanced ovarian serous carcinoma.

scholarly journals Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas

2010 ◽  
Vol 2010 ◽  
pp. 1-12 ◽  
Author(s):  
Stefanie M. Ueda ◽  
Kai Lee Yap ◽  
Ben Davidson ◽  
Yuan Tian ◽  
Vivek Murthy ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Fatty Acid ◽  
Cancer Cells ◽  
Fatty Acid Synthase ◽  
Dominant Negative ◽  
Serous Carcinoma ◽  
Ovarian Cancer Cells ◽  
Primary Tumors ◽  
Ovarian Serous Carcinoma ◽  
Skov3 Cells

Our previous reports demonstrated that NAC1, a BTB/POZ domain-containing nuclear protein, upregulates in recurrent ovarian serous carcinoma and participates in developing drug resistance in cancer cells. The current study applies quantitative proteomics to identify the proteins controlled by NAC1 by comparing the proteomes of SKOV3 cells with and without expression of a dominant negative NAC1 construct, N130. From the proteins that are downregulated by N130 (upregulated by NAC1), we chose to further characterize fatty acid synthase (FASN). Similar to change in protein level, the FASN transcript level in SKOV3 cells was significantly reduced by N130 induction or by NAC1 knockdown. Immunohistochemistry showed that NAC1 and FASN immunointensities in ovarian serous carcinoma tissues had a highly significant correlation (P<.0001). Moreover, we found that recurrent serous carcinomas exhibited higher FASN immunointensities than their matched primary tumors (P<.001). Multivariate analysis showed that an FASN staining score of >1 in serous carcinomas was associated with a worse overall survival time (P<.01). Finally, C93, a new FASN inhibitor, induced massive apoptosis in carboplatin/paclitaxel resistant ovarian cancer cells. In conclusion, we show that NAC1 is essential for FASN expression in ovarian serous carcinomas and the expression of FASN significantly correlates with tumor recurrence and disease aggressiveness. The dependence of drug resistant tumor cells on FASN suggests a potential application of FASN-based therapeutics for recurrent ovarian cancer patients.

scholarly journals Coumestrol suppresses proliferation of ES2 human epithelial ovarian cancer cells

2015 ◽  
Vol 228 (3) ◽  
pp. 149-160 ◽  
Author(s):  
Whasun Lim ◽  
Wooyoung Jeong ◽  
Gwonhwa Song
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clear Cell ◽  
Serous Carcinoma ◽  
Ovarian Cancer Cells ◽  
Dependent Manner ◽  
Pi3k Inhibitors ◽  
Novel Treatment ◽  
Induced Apoptosis ◽  
Preventive Effects

Coumestrol, which is predominantly found in soybean products as a phytoestrogen, has cancer preventive activities in estrogen-responsive carcinomas. However, effects and molecular targets of coumestrol have not been reported for epithelial ovarian cancer (EOC). In the present study, we demonstrated that coumestrol inhibited viability and invasion and induced apoptosis of ES2 (clear cell-/serous carcinoma origin) cells. In addition, immunoreactive PCNA and ERBB2, markers of proliferation of ovarian carcinoma, were attenuated in their expression in coumestrol-induced death of ES2 cells. Phosphorylation of AKT, p70S6K, ERK1/2, JNK1/2, and p90RSK was inactivated by coumestrol treatment in a dose- and time-dependent manner as determined in western blot analyses. Moreover, PI3K inhibitors enhanced effects of coumestrol to decrease phosphorylation of AKT, p70S6K, S6, and ERK1/2. Furthermore, coumestrol has strong cancer preventive effects as compared to other conventional chemotherapeutics on proliferation of ES2 cells. In conclusion, coumestrol exerts chemotherapeutic effects via PI3K and ERK1/2 MAPK pathways and is a potentially novel treatment regimen with enhanced chemoprevention activities against progression of EOC.

scholarly journals ES-2 Ovarian Cancer Cells Present a Genomic Profile Inconsistent with their Reported History

2020 ◽  
Author(s):  
Eric J. Devor ◽  
Jace R. Lapierre ◽  
Kimberly K. Leslie ◽  
David P. Bender
Keyword(s):  
Ovarian Cancer ◽  
Cell Carcinoma ◽  
Cancer Cells ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Serous Carcinoma ◽  
Ovarian Cancer Cells ◽  
African American Patient ◽  
American Patient ◽  
Carcinoma Of The Ovary

Abstract Objective: ES-2 ovarian cancer cells have long been reported to have originated from a primary clear cell carcinoma of the ovary presenting in a 47 year-old African American patient. Two recent publications have offered evidence calling both of these characteristics into question. Our objective was to further study this cell line using quantitative real-time PCR (qPCR) and mitochondrial DNA (mtDNA) sequencing in order to confirm or refute these inconsistencies.Results: qPCR assays on two characteristic loci, hepatocyte nuclear factor 1β (NHF-1β) and glutathione peroxidase 3 (GPX3), suggest that ES-2 are unusual clear cell carcinoma cells that appear more like high grade serous carcinoma than clear cell. Further, mtDNA haplotyping places the ancestral origin of the patient’s lineage in the Middle East or Europe and not Africa. These results are consistent with and support the conclusions of the two recent publications.

Serum biomarker discovery for ovarian serous carcinoma using novel proteomic methods

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 16058-16058 ◽  
Author(s):  
J. A. Borgia ◽  
C. Frankenberger ◽  
K. Kaiser ◽  
S. E. McCormack ◽  
L. Usha ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Biomarker Discovery ◽  
Tumor Resection ◽  
Stage I ◽  
Serum Biomarker ◽  
Serous Carcinoma ◽  
Major Surgery ◽  
Ovarian Serous Carcinoma ◽  
Baseline Subtraction ◽  
Operative Specimen

16058 Background: Ovarian serous carcinoma (OSC) is the most common ovarian cancer sub-type and fourth leading cause of cancer-related deaths for women in the US. Unfortunately, more than two-thirds of women with ovarian cancer present at an advanced stage, when prognosis is poor. Developing methods to detect ovarian cancer at stage I, when it is 90% curable by surgery, or at stage II where survival is 70%, offers the best prospect for changing the clinical course of this dread malignancy. Methods: Serum specimens were collected both before and 3–6 weeks after tumor resection for patients with Stage I/ II high-grade serous carcinoma. None suffered recurrence within 6 months. We collected 98 ‘paired’ (pre- and post operative) serum specimens; including 41 benign paired specimens for comparison. A SELDI-TOF mass spectrometer was used to generate the serum proteomic profiles, optimized for the 2,000–40,000 m/z range. All data analyses were performed in a blinded manner using Bioconductor, an extension of the R-project statistical platform (v2.2.0). Raw spectra were processed as follows: baseline subtraction, spectra normalization, and differential peak detection. Aligned peaks were sorted into groups, based on tumor pathology and pre- vs. post-operative specimen type, and compared using a two tailed homoscedastic t-test. Results: The proteomes of pre- and post-operative serum from 10 patients with OSC were evaluated for significant changes in composition and compared with a set of 8 ‘normal’ specimens (i.e. patients undergoing major surgery for benign disease). We identified 18 serum components common to all OSC pre-op specimens that were extensively reduced or absent (p < 0.05) after tumor resection and 26 components capable of discerning pre-op OSC from pre-op normal specimens (p < 0.05). Most notable of these are components with m/z ratios of 2029.1, 2203.6, 6442.3, and 6851.9, based on level of significance (p < 0.001). Conclusions: These results validate the power of our ‘pre- vs. post- operative’ analysis strategy for the identification of novel serum biomarker candidates. Efforts are currently focused on expanding the scope of our specimen bank and identifying the putative biomarker candidates via mass spectrometry. No significant financial relationships to disclose.

scholarly journals Breast Carcinomatous Lymphangitis as an Unusual Presentation of Ovarian Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 2106
Author(s):  
Barbara Muoio ◽  
Giorgio Treglia ◽  
Paola Migliora ◽  
Maria Del Grande
Keyword(s):  
Ovarian Cancer ◽  
Diagnostic Laparoscopy ◽  
Unusual Presentation ◽  
Serous Carcinoma ◽  
Ovarian Serous Carcinoma ◽  
Abdomen Ct ◽  
History Of ◽  
Ovarian Lesion ◽  
The Right ◽  
Ovarian Masses

We describe the case of a 45-year-old woman with an unusual presentation of metastatic ovarian cancer. The patient presented to the oncological clinic with a three-week history of skin rash on the right breast. She underwent a chest and abdomen CT scan, which showed skin thickening of the right breast, right pleural effusion and bilateral cystic ovarian masses. Biopsy of a left ovarian lesion by diagnostic laparoscopy revealed the presence of ovarian serous carcinoma. Biopsy of the breast skin lesion revealed the presence of carcinomatous lymphangitis and immunohistochemistry documented the ovarian origin.

scholarly journals Immunohistochemical expression of human epididymis 4 in ovarian malignancy

2019 ◽  
Vol 7 (12) ◽  
pp. 4493
Author(s):  
Begum Afrin Nahar ◽  
Rama Saha ◽  
Chhanda Das ◽  
Gourishankar Kamilya
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Neoplasm ◽  
Serous Carcinoma ◽  
Ovarian Cancer Cells ◽  
High Grade ◽  
Ovarian Malignancy ◽  
Endometrioid Carcinoma ◽  
Immunohistochemical Expression ◽  
Human Epididymis ◽  
Cancer Support

Background: Ovarian malignancies has the highest mortality rate among all gynaecological malignancies. Surface epithelial tumors form two thirds of all ovarian neoplasm and 90% of all ovarian cancers are surface epithelial carcinomas. Mortality in case of ovarian malignancy is high due to late diagnosis. Early and accurate diagnosis can improve the case specific management. HE4 (Human Epididymis Protein 4) which is proved to be overexpressed in the ovarian cancer cells, is considered a new biomarker for ovarian cancer diagnosis which helps in early diagnosis and patient management. Aims and objectives of the study was to evaluate the immunohistochemical expression of HE4 in various ovarian malignancies.Methods: It was a cross sectional, prospective, single institution-based study, conducted in the department of Pathology in collaboration with the Department of Gynaecology and Obstetrics, from December 2016 to January 2019 in institution. A total 74 ovarian malignancies were selected for this study.Results: Serous carcinoma was the most common ovarian malignancy followed by endometrioid carcinoma. Highest percentage of expression of HE4 was seen in high grade serous cancer and malignant endometrioid tumor.Conclusions: HE4 was highly expressed in malignant ovarian tumour especially serous and endometrioid carcinoma and can be used as an important biomarker for malignant ovarian neoplasm. Expression in high grade ovarian serous cancer support its prognostic value also.

scholarly journals Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells

Cancers ◽  
2021 ◽  
Vol 13 (18) ◽  
pp. 4617
Author(s):  
Evgeny Chirshev ◽  
Tise Suzuki ◽  
Hanmin Wang ◽  
Anthony Nguyen ◽  
Nozomi Hojo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Progression ◽  
Gynecological Cancer ◽  
Parp Inhibitor ◽  
Serous Carcinoma ◽  
Migration And Invasion ◽  
Ovarian Cancer Cells ◽  
Brca Mutations ◽  
Term Survival ◽  
Increased Sensitivity

High-grade serous carcinoma of the ovary is a deadly gynecological cancer with poor long-term survival. Dysregulation of microRNAs has been shown to contribute to the formation of cancer stem cells (CSCs), an important part of oncogenesis and tumor progression. The let-7 family of microRNAs has previously been shown to regulate stemness and has tumor suppressive actions in a variety of cancers, including ovarian. Here, we demonstrate tumor suppressor actions of let-7i: repression of cancer cell stemness, inhibition of migration and invasion, and promotion of apoptosis, features important for cancer progression, relapse, and metastasis. Let-7i over-expression results in increased sensitivity to the PARP inhibitor olaparib in samples without BRCA mutations, consistent with induction of BRCAness phenotype. We also show that let-7i inhibits the expression of several factors involved in the homologous recombination repair (HRR) pathway, providing potential mechanisms by which the BRCAness phenotype could be induced. These actions of let-7i add to the rationale for use of this miRNA as a treatment for ovarian cancer patients, including those without mutations in the HRR pathway.

Sign in / Sign up

Export Citation Format

Share Document